• Markets
    • icon
  • Companies
IXC · ASX

Invex Therapeutics Ltd. (ASX:IXC)

AU$0.072

 0.0 (0.0%)
ASX:Live
25/07/2024 12:00:00 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IXC Overview

IXC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About IXC

Website

Invex Therapeutics Ltd.

Telephone

N/A

Address

Description

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. It focuses on understanding and defining the mechanisms that regulate pressure in the brain and aims to repurpose and reformulate an already approved drug, Exenatide. The company was founded by Jason Loveridge and Alexandra J. Sinclair on March 8, 2019 and is headquartered in Subiaco, Australia.

IXC Price Chart

Key Stats

Market Cap

AU$5.41M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.1

Trade Value (12mth)

AU$1,446.00

1 week

-5.26%

1 month

2.86%

YTD

-13.25%

1 year

48.72%

All time high

0.52

Key Fundamentals

EPS 3 yr Growth

72.400%

EBITDA Margin

N/A

Operating Cashflow

-$7m

Free Cash Flow Return

-27.60%

ROIC

-31.20%

Interest Coverage

N/A

Quick Ratio

14.50

Other Data

Shares on Issue (Fully Dilluted)

75m

HALO Sector

Healthcare

Next Company Report Date

15-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

IXC Announcements

Latest Announcements

Date Announcements

23 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

01 July 24

Final Director's Interest Notice

×

Final Director's Interest Notice

26 June 24

Notification of cessation of securities - IXC

×

Notification of cessation of securities - IXC

21 June 24

Invex receives R&D Tax Rebate

×

Invex receives R&D Tax Rebate

18 June 24

Resignation of Dr Megan Baldwin

×

Resignation of Dr Megan Baldwin

19 April 24

Details of Auditor Appointment/Resignation

×

Details of Auditor Appointment/Resignation

12 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

09 April 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

08 April 24

Notification of cessation of securities - IXC

×

Notification of cessation of securities - IXC

03 April 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

22 March 24

Amendment to Appendix 3A.4

×

Amendment to Appendix 3A.4

20 March 24

ATO Class Ruling Return of Capital

×

ATO Class Ruling Return of Capital

05 March 24

Update on R&D Tax Rebate from UK Government

×

Update on R&D Tax Rebate from UK Government

16 February 24

Appendix 4D and Half year report

×

Appendix 4D and Half year report

11 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 December 23

Notification of cessation of securities - IXC

×

Notification of cessation of securities - IXC

22 December 23

Invex and Peptron Mutually Terminate Manufacturing Agreement

×

Invex and Peptron Mutually Terminate Manufacturing Agreement

05 December 23

Results of Meeting

×

Results of Meeting

05 December 23

Effective Date of Capital Return

×

Effective Date of Capital Return

30 November 23

Payment of Capital Return Proceeds

×

Payment of Capital Return Proceeds

28 November 23

Change in substantial holding

×

Change in substantial holding

28 November 23

Chair's Address to Shareholders

×

Chair's Address to Shareholders

28 November 23

Results of Meeting

×

Results of Meeting

27 November 23

Change of Director's Interest Notice x 3

×

Change of Director's Interest Notice x 3

22 November 23

Invex Granted European Patent for Exenatide in Hydrocephalus

×

Invex Granted European Patent for Exenatide in Hydrocephalus

IXC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.05 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.05 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 49.2 -73.0 -96.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.05 -0.10 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.04 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.8 -109.2 -101.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.5 -9.1 -45.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.43 0.38 0.28 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.43 0.38 0.28 Lock Lock Lock
     Growth % Lock Lock Lock Lock 18.1 -11.2 -25.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 75 75 75 Lock Lock Lock
Basic m Lock Lock Lock Lock 75 75 75 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 4 9 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 -4 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 28.3 -71.5 -115.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -2 -4 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 28.3 -71.5 -115.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -2 -4 -8 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -4 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 32.0 -73.1 -96.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -3 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 8 0 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -3 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4.7 -101.2 -103.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 33 29 22 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 33 29 23 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -33 -29 -22 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 32 28 21 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 32 28 21 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.5 -11.2 -25.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -7.0 -13.4 -34.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -7.1 -13.9 -36.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -8.6 -13.8 -36.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -8.1 -13.1 -31.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -5.9 -11.2 -27.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 13.4 7.0 2.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -102.0 -103.0 -105.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 49.7 29.4 14.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 49.7 29.4 14.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 99.9 99.5 98.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -254.8 -336.3 -436.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -7.0 -13.4 -34.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -7.1 -13.9 -36.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -7.1 -13.9 -36.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IXC Shortsell

Frequently Asked Questions

The current share price of Invex Therapeutics Ltd. (IXC:ASX) is AU$0.072.
The 52-week high share price for Invex Therapeutics Ltd. (IXC:ASX) is AU$0.10.
The 52-week low share price for Invex Therapeutics Ltd. (IXC:ASX)? is AU$0.04.
Invex Therapeutics Ltd. (IXC:ASX) does not pay a dividend.
The last dividend payment of Invex Therapeutics Ltd. (IXC:ASX) is AU$1.19.
Invex Therapeutics Ltd. (IXC:ASX) has a franking level of 0.0%.
Invex Therapeutics Ltd. (IXC:ASX) is classified in the Healthcare.
The current P/E ratio for Invex Therapeutics Ltd. (IXC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.